lifewave patches glutathione Y-age Phototherapy Patches, 30 - Exp 04/2027 LifeWave Y-Age Glutathione Patches -

Designed for Real-World Results B12 Methylcobalamin Active, bioavailable B12 that supports: Red blood cell formation and prevents megaloblastic anemia Nervous system health (myelin maintenance, neurotransmitter synthesis) Methylation (homocysteine methionine) for cardiovascular/cellular health Energy metabolism Uses: Treats B12 deficiency (fatigue, weakness, paresthesia, cognitive issues) For malabsorption, vegetarians/vegans, older adults, or those on B12impairing meds May support mood and cognition (results vary) L-Carnitine What it is An amino acid derivative that transports long-chain fatty acids into mitochondria for energy

Are you GMP manufacture

What the Research Does NOT Yet Support - There are currently no published randomised controlled trials (RCTs) in humans for BPC-157 - Human pharmacokinetic data (how it is absorbed, distributed, metabolised, and excreted) is limited - Optimal dosing, route of administration, and treatment duration have not been established clinically - Long-term safety data in humans is absent - Regulatory approval from the TGA, FDA, or EMA has not been granted for any therapeutic indication TB-500: Evidence Overview What the Research Supports TB-500 / Thymosin Beta-4 has somewhat more human-facing research, though still predominantly preclinical: Phase I and II clinical trials have investigated Thymosin Beta-4 (the native peptide) in cardiac repair following myocardial infarction, with promising safety profiles Wound healing applications have been explored in clinical settings, particularly for chronic non-healing wounds and dry eye disease Robust animal evidence supports its role in reducing inflammation, supporting angiogenesis, and promoting tissue regeneration The native peptide (T4) has demonstrated cardioprotective effects in animal models of heart failure and ischaemia What the Research Does NOT Yet Support TB-500 is a synthetic fragment of T4 it is not identical to the native peptide, and extrapolating human clinical data from T4 studies directly to TB-500 may not be valid No approved therapeutic indications exist for TB-500 specifically Comparative efficacy versus established treatments has not been studied The long-term effects of exogenous peptide administration on endogenous thymosin beta-4 regulation are unknown Potential Benefits: A Summary Based on the available (predominantly preclinical) literature, the following potential benefits have been identified: Risks & Safety Considerations Known & Reported Side Effects Because large-scale human trials are lacking, our understanding of the side effect profile is limited

Intended strictly for professional research use

BPC157 A synthetic peptide sequence that has been widely referenced in laboratory studies exploring connective signaling pathways and other molecular mechanisms

The proposed model based on mutagenesis and structural analyses suggests that alcohol stabilizes the open conformation of GIRK channels by displacing amino acids in the closed state, particularly at the base of the alcohol pocket ( FIGURE 4 In a study employing an alcohol tagging approach with GIRK2, He et al., 2002